Intra-cellular therapies reports third quarter 2022 financial results and provides corporate update

Caplyta net product revenues for the third quarter 2022 were $71.9 million, compared to $21.6 million for the same period in 2021, representing a 233% increase over the same period in 2021 and a 30% increase over the second quarter 2022

ITCI Ratings Summary

ITCI Quant Ranking